The impact of prevalent primary cancers in melanoma patients on survival - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Influence of Existing Primary Cancers on Survival Outcomes in Melanoma Patients

  • By

  • Alessandra Buja

  • Stefano Guzzinati

  • Chiara Trevisiol

  • Claudio Palmeri

  • Marcello Di Pumpo

  • Paolo Del Fiore

  • Carlo Riccardo Rossi

  • Carmen Stocco

  • Pierfranco Conte

  • Manuel Zorzi

  • Simone Mocellin

  • September 14, 2026

Share

  • 1

    A study of 2,978 melanoma patients found that 4.5% had prevalent primary cancers diagnosed within five years prior to melanoma.

  • 2

    Common prevalent cancers included prostate (30.2%), breast (10.8%), colon (7.9%), and kidney (7.2%) cancers.

  • 3

    Prevalent tumors were associated with increased all-cause mortality risk, with an adjusted hazard ratio of 1.72.

  • 4

    No significant association was found between prevalent tumors and melanoma-specific mortality.

  • 5

    Healthcare costs were higher for patients with prevalent tumors, averaging €30,698.34 compared to €17,471.23 for those without.

Original Source(s)

The impact of prevalent primary cancers in melanoma patients on survival

  • by Alessandra Buja, Stefano Guzzinati, Chiara Trevisiol, Claudio Palmeri, Marcello Di Pumpo, Paolo Del Fiore, Carlo Riccardo Rossi, Carmen Stocco, Pierfranco Conte, Manuel Zorzi, Simone Mocellin

  • September 14, 2026

Related Content

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma